Baker Bros. Advisors LP 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Baker Bros. Advisors LP | 10,204,089 4.980% | -8,980,705 (-46.81%) | Filing |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Baker Bros. Advisors LP | 19,184,794 9.950% | 720,050 (+3.90%) | Filing |
| 2022-02-14 4:15 pm Purchase | 2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Baker Bros. Advisors LP | 18,464,744 9.950% | 285,863 (+1.57%) | Filing |
| 2021-02-16 4:53 pm Purchase | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Baker Bros. Advisors LP | 18,178,881 9.990% | 2,303,756 (+14.51%) | Filing |